National Heart Institute

Gerontology Branch, National Heart Institute, National Institutes of Health, U. S. Department of Health, Education and Welfare,... 

Merker, R. L., Eliash, L. J., Mayhew, S. H., Wang, J. Y. C. Artificial Heart Program Conference Proceedings. Ed. Hegyeli, R. J., Washington National Heart Institute Artificial Heart Program 1969 p. 29... 

Supported by a grant-in-aid from the National Heart Institute, U. S. Public Health Service. 

We gratefully acknowledge the support provided us by the National Heart Institute of the National Institutes of Health, through Contract No. 

Recent investigatioins at the National Heart Institute, Bethesda, Maryland, and the Rockefeller Institute for Medical Research, New York, indicate that the sequence of ribonuclease involving residues 11 through 18 is incorrect as shown in Fig. 17. The correct sequence will be published shortly by both of the laboratories (personal communication from C. B. Anfinsen). 

Fig. 19. Topography of the NBS cleavage of the six tyrosyl peptide links of native and

I am greatly obligated to my colleagues and associates at the National Institutes of Health who contributed experimentally, conceptually, and editorially to this chapter. Special thanks are due to Drs. L. A. Cohen, E. Gross, and W. B. Lawson. Dr. C. B. Anfinsen, National Heart Institute, and Drs. A. Berger, A. Patchornik, and M. Sela from the Weizmann Institute were extremely helpful in making unpublished material available prior to publication. To them and many other cooperative authors I extend my sincere thanks. 

Dopamine (DO) was discovered by Arvid Carlsson and Jils-Ake Hillarp at the Laboratory for Chemical Pharmacology of the National Heart Institute of Sweden, in 1952. 

In the past few years, the chemistry and pharmacology of the catecholamines and their metabolic inhibitors have been the subject of intensive investigation in many parts of the world but especially by Sjoerdsma and Axelrod at the National Heart Institute. Monoamine oxidase inhibitors have been tried in the treatment of hypertension with both uncertain results and uncertain rationale. Recently, the decarboxylase inhibitor, methyldopa, has been widely recommended in the treatment of hypertension, though, again, the evidence gives no clear idea as to how it works. 

K. C. Moran, unpublished data. National Heart Institute, 1953-1956. 

Christian Boehmer Anfinsen was born in Monessen, Pennsylvania, on March 26, 1916. He earned a B.A. from Swarthmore College in 1937 and an M.S. from the University of Pennsylvania in 1939. In 1943 he received a Ph.D. in biochemistry from Harvard Medical School. He remained at Harvard for seven more years as an instructor and assistant professor of biological chemistry. In 1950 Anfinsen assumed the position of director of the Laboratory of Cellular Physiology and Metabolism at the National Heart Institute of the National Institutes of Health (NIH). This move led to a period of thirty years when he split his time between Harvard and the NIH until his retirement in 1981. 

This work was supported by grant No. 5 ROL He 08344 from the National Heart Institute, National Institutes of Health. Some of the material presented here was taken from a report by E. Frieden and S. Osaki to the Second Rochester Conference on Toxicity, Heavy Metals and Cells, in June I960. Appreciation is expressed to C. E. Cartwright for making available information in advance of publication. This is paper No. 37 from this laboratory in a series on copper biosystems. 

We wish to thank Mrs. Lillian Haas, Miss Jane T. Kolimaga, and Mrs. Rose Powdermaker for their assistance with the editing of this volume. This work was supported in part by grants AM-02131, General Research Support 5SO-1RR-05479 (PPN), HE-03299, HE-05209, and a National Heart Institute Research Career Award (DK), K6-HE-734 from the National Institutes of Health, United States Public Health Service. 

Obtained through the courtesy of V. Massey, University of ShefEeld, England D. R. Sanadi, National Heart Institute, NIH and L. J. Reed, University of Texas, Austin, Texas. The above value refers to a commercial sample. 

P. N. Sawyer and S. Srinivasan, New Approaches in the Selection of Materials Compatible with Blood, Annual Reports on Contract PH-68-75 for 1968-1970 (submitted to Medical Devices and Application Program), National Heart Institute, National Institute of Health. 

Sponsored by the National Heart Institute and the United States Public Health Service. 

Metabolism of Drugs and Other Foreign Compounds by Enzymatic Mechanisms 6,11 (1963) Dr. J. R. Gillette Head, Section on Enzymes Drug Interaction, Laboratory of Chemical Pharmacology, National Heart Institute, Bethesda 14, Maryland, USA... 

In 1957 he was invited by Prof. Earl Stadtman to go to the Laboratory of Biochemistry at the National Heart Institute, Bethesda, Maryland, USA. He stayed there until 1959, studying the mechanism of biological catabolism of branched carbon chains on models such as farnesole and geraniole. When he came back to Munich, he continued these studies on the metabolism of terpenes. 

Comment - Several interesting developments have occurred in 1968, but the atherosclerosis problems are far from solved. A large scale drug test has been started by the National Heart Institute, which should indicate the usefulness of several drugs. In his Duff Memorial Lecture, Page called for "better research" "reduce the amount of almost trivial, repetitive, Investigation and increase the number of fresh creative starts." ... 

The National Cancer Institute The National Heart Institute... 

This method was developed in the course of research supported by the U. S. Atomic Energy Commission, the Life Insurance Medical Research Fund, and the Nations) Heart Institute of the U. S. Public Health Service. The ultracentrifugal analytic method described here evolved from the combined efforts of many members of the biophysical chemistry research group at the Donner Laboratory. 

The contributions of Drs. William Goss, Andrew Sivak, Lois Salzman and Mr. T. Yoshida are gratefully acknowledged. Many of the investigations have been carried out in collaboration with Dr. Herbert Weissbach of the National Heart Institute, N.I.H. 

Very shortly after this finding, a concerted effort was begun in 1964 to find or develop thromboresistant pol3rmers. This effort was the biomaterial portion of the Artificial Heart Program of the National Heart Institute, Descriptions of the approaches taken and progress made have been published in some detail. The early work on individual polymers is not described or referenced here because of space limitation. Consult references (2) and (3) for more specific information. These early efforts were in directions such as ... 

---